ММВБ 2 373 -2,6%  Nasdaq 11 355 -0,3%  Биткойн 30 104 -0,8%  USD/RUB 60,0250 -3,2% 
РТС 1 240 -0,5%  S&P500 3 901 0,0%  Нефть 113,1 0,2%  EUR/RUB 63,5935 -2,9% 
Dow 31 262 0,0%  FTSE100 7 390 1,2%  Золото 1 854 0,4%  EUR/USD 1,0593 0,4% 

Iovance Biotherapeutics - Профиль

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Акционеры

Название Доля (%)
Freefloat88,52
The Vanguard Group, Inc.7,76
Perceptive Advisors LLC6,44
Wellington Management Co. LLP6,10
Avoro Capital Advisor LLC5,52
Quogue Capital LLC4,50
Franklin Advisers, Inc.3,67
Xtrackers SICAV - S&P 500 Swap UCITS ETF2,39
Nikko AM Global Umbrella Fund - ARK Disruptive Innovation2,03
Armistice Capital LLC1,91
Frazier Management LLC1,11
Norges Bank (13F)0,83
Lord, Abbett & Co. LLC0,70
Jeffrey Robert Jay, MD0,59

Адрес

а/я:
Телефон:
Факс:
Вэб:

Менеджмент

Добавить или редактировать инструмент